Pre-Test Bruton’s Tyrosine Kinase Inhibitors as a Target Pre-Test Which of the following statements best describe results from the Alpine study? Zanubrutinib improved PFS in patients with del(17p)/TP53mut exhibiting an improved cardiac profile and a decreased incidence of treatment discontinuation as compared to ibrutinib Zanubrutinib improved PFS in patients without del(17p)/TP53mut exhibiting an improved cardiac profile and a decreased incidence of treatment discontinuation as compared to ibrutinib Zanubrutinib improved PFS in patients with del(17p)/ TP53mut exhibiting an improved cardiac profile and an increased incidence of treatment discontinuation as compared to ibrutinib Zanubrutinib improved PFS in patients without del(17p)/TP53mut exhibiting an improved cardiac profile and a decreased incidence of treatment discontinuation as compared to ibrutinib Unsure In the BGB-3111-215 study, CLL/SLL patients formerly intolerant to acalabrutinib and/or ibrutinib, disease was controlled in ____ of zanubrutinib treated patients. 65% 75% 85% 95% Unsure Which of the following best describes four-year follow-up results from the fixed duration cohort in the CAPTIVATE study? PFS 59%, OS 78%, with atrial fibrillation the most common AE in retreatment PFS 59%, OS 78%, with diarrhea and anemia the most common AEs in retreatment PFS 79%, OS 98%, with atrial fibrillation the most common AE in retreatment PFS 79%, OS 98%, with diarrhea and anemia the most common AEs in retreatment Unsure Which of the following combinations trial resulted in significantly longer overall survival in treatment naïve CLL patients at 5 years post-treatment when compared to chlorambucil + obinutuzumab? Acalabrutinib + obinutuzumab Ibrutinib + obinutuzumab Tirabrutinib + obinutuzumab Zanubrutinib + obinutuzumab Unsure How confident are you in your ability to incorporate real- world evidence and knowledge of adverse event management to improve outcomes of CLL patients? Very confident Confident Somewhat confident Not very confident Not at all confident
